Weighing in: Emergent diabetes mellitus and second-generation antipsychotics

Annals of Pharmacotherapy

Volumn 41, Issue 10, 2007, Pages 1725-1727

  Dufresne, Robert L ^a,b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Diabetes mellitus; Hypertriglyceridemia; Obesity

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DIABETES MELLITUS; DRUG EFFECT; DRUG MONITORING; HUMAN; HYPERTRIGLYCERIDEMIA; KETOACIDOSIS; LIPID BLOOD LEVEL; METABOLIC ACIDOSIS; OBESITY; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; HUMANS; OBESITY; WEIGHT GAIN;

EID: 34748814841     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K362     Document Type: Review

References (21)

1. Citrome LL, Holt RIG, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41:1593-603. Epub 4 Sept 2007. DOI 10.1345/aph.1K141
2. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
3. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:2079-81.
4. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-2.
5. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-70.
6. Package insert. Seroquel (quetiapine fumarate). Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2003.
7. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994;151:1520-1.
8. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001;111:716-23.
9. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-52.
10. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735-44.
11. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857-63.
12. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
13. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007;20:131-7.
14. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
15. Moller HJ. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer to the CATIE study. Eur Arch Psychiatry Clin Neurosci 2005;255:371-2.
16. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
17. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
18. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81.
19. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007;27:159-69.
20. ADA; APA; ASCE; NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72.
21. Marder SR, Essock SM, Miller AL, et al. The Mt. Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002;28:5-16.